Patient Access

6,000 pharmacy professionals attended Asembia this year. What were the key takeaways from the conference?

Plan sponsors are looking for new ways to contain specialty costs. How should they evaluate new copay assistance strategies?

With so much importance placed on the launch of a new drug, how should pharma brands ensure a successful launch?  

With Delta and Omicron, the COVID-19 pandemic carries on. How are these variants impacting pharma brands?

Many brands experience a drop in claims during January. What strategies successfully drive adherence during the beginning of the year?

Four core themes from Asembia 2021 that will drive dialogue in the specialty pharmacy ecosystem in 2022 – and beyond.

Truveris’ Life Sciences data science team conducted a deep-dive analysis to assess the impact of COVID-19 on prescribing and claim volume throughout an 18-month span.

Loss of exclusivity can feel like a dramatic shift, forever changing a drug’s profitability. However, this doesn’t have to be your brand’s fate.

Many Medicare patients end up not filling their high-cost prescriptions due to the Medicare coverage gap. What can manufacturers do to help Medicare patients stay adherent? 

Using simple patient inputs to provide a customized view of specific coverage restrictions and out-of-pocket cost obligations, real-time benefits checks empower patients and providers to make informed decisions about care.

Adopting these three approaches can help manufacturers to build a more effective affordability program. 

You likely already know what patient abandonment is: when a prescription is written by a doctor but never picked up at the pharmacy.